uniQure (QURE) CEO Matthew Kapusta Sells $7.3M of Stock
CEO Matthew Kapusta parted with 164,429 shares of uniQure N.V. stock in a transaction valued at about $7.29 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Matthew Kapusta, CEO, Managing Director at uniQure N.V. ($QURE), sold 164,429 shares at an average price of $44.32, worth about $7.29 million, on June 17, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $QURE is up 1.4% after 1 week, down 16.4% after 1 month and down 54.8% to date (from the $48.16 close on Jun 17, 2026).
QURE
uniQure N.V.
Key Points
- uniQure N.V. CEO Matthew Kapusta sold 164,429 shares of stock at an average price of $44.32 on June 17, 2026, for a total value of $7,288,068.78.
- The stock trades around $45.77, well above its 200-day moving average of $29.66, following a volatile 52-week range.
- Several Wall Street firms have updated their stances, with Barclays recently lowering its price target to $28 while other firms maintain higher outlooks.
Get $QURE trade alerts by text
We text you when insiders, Congress or big funds trade $QURE. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated uniQure N.V. alert may contain errors. Disclosures
CEO Matthew Kapusta Sells 164,429 Shares of uniQure N.V.
uniQure N.V. (NasdaqGS: QURE) CEO and Managing Director Matthew Kapusta sold 164,429 shares of the company on June 17, 2026. The shares were sold at an average price of $44.32, bringing the total value of the transaction to $7,288,068.78. This planned sale follows a series of active trading moves by the executive, who has also made multiple purchases and sales of company shares over the summer months.
uniQure Stock Moves Higher Near 50-Day Average
Shares of uniQure traded around $45.77 on Monday, sitting comfortably above the 200-day moving average of $29.66 and just above the 50-day moving average of $40.20. The biotechnology company has experienced a wide trading range over the past year, with a 52-week low of $8.73 and a 52-week high of $71.50. The company carries a market capitalisation of approximately $1.56 billion.
Insider Buying and Selling at uniQure N.V.
Executive transactions at uniQure have kept a steady pace alongside the CEO's sales. Chief Medical Officer Walid Abi-Saab sold 1,434 shares on June 26, 2026, at an average price of $46.86 for a total of $67,197.24. Earlier in the month on June 24, 2026, CEO Matthew Kapusta bought 4,128 shares at $31.71 each, and also sold 4,128 shares at $50.00 each under a planned arrangement. On June 17, 2026, Kapusta bought 62,581 shares at $19.39 per share, totaling $1,213,445.59, while board member Madhavan Balachandran also engaged in transactions on the same date.
Analysts Set New Price Targets
Analyst coverage for uniQure features a mix of rating adjustments and price target revisions. On October 5, 2026, Barclays downgraded the stock to an Equal-Weight rating and cut its price target from $60.00 to $28.00. Earlier, on October 2, 2026, RBC Capital maintained an Outperform rating while lowering its target from $65.00 to $48.00. Goldman Sachs maintained a Neutral rating with a $31.00 target on September 30, 2026. Overall, the stock holds a consensus recommendation of strong buy with a mean price target of $61.46 across 12 analyst opinions.
Developing Gene Therapies in Amsterdam
Headquartered in Amsterdam, Netherlands, uniQure N.V. focuses on developing treatments for patients with rare and devastating diseases. The company offers HEMGENIX for hemophilia B and advances several pipeline candidates, including AMT-130 for Huntington's disease, AMT-260 for mesial temporal lobe epilepsy, and AMT-191 for Fabry disease.
What to Watch Next for QURE
Investors will look ahead to uniQure's next earnings report, scheduled for November 9, 2026, for further updates on its clinical trials and financial standing. Insider filings and upcoming analyst notes will continue to provide visibility into how management and market watchers view the company's valuation.
Related Filing Alerts
Source: Matthew Kapusta's Form 4 filing on $QURE (Jun 17, 2026). Find the original filing: QURE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts